A detailed history of Swiss National Bank transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Swiss National Bank holds 286,600 shares of TGTX stock, worth $9.09 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
286,600
Previous 288,600 0.69%
Holding current value
$9.09 Million
Previous $5.13 Million 30.56%
% of portfolio
0.0%
Previous 0.0%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

SELL
$17.21 - $25.28 $34,420 - $50,560
-2,000 Reduced 0.69%
286,600 $6.7 Million
Q2 2024

Aug 08, 2024

BUY
$13.32 - $19.19 $59,940 - $86,355
4,500 Added 1.58%
288,600 $5.13 Million
Q1 2024

May 07, 2024

BUY
$13.02 - $21.3 $19,530 - $31,950
1,500 Added 0.53%
284,100 $4.32 Million
Q4 2023

Feb 06, 2024

SELL
$6.68 - $18.81 $196,392 - $553,014
-29,400 Reduced 9.42%
282,600 $4.83 Million
Q3 2023

Nov 08, 2023

BUY
$8.36 - $26.5 $77,748 - $246,450
9,300 Added 3.07%
312,000 $2.61 Million
Q2 2023

Aug 09, 2023

BUY
$15.48 - $35.0 $72,756 - $164,500
4,700 Added 1.58%
302,700 $7.52 Million
Q1 2023

May 10, 2023

SELL
$10.23 - $19.34 $360,096 - $680,768
-35,200 Reduced 10.56%
298,000 $4.48 Million
Q4 2022

Feb 08, 2023

BUY
$5.01 - $11.83 $39,078 - $92,274
7,800 Added 2.4%
333,200 $3.94 Million
Q3 2022

Nov 09, 2022

BUY
$4.57 - $8.4 $25,135 - $46,200
5,500 Added 1.72%
325,400 $1.93 Million
Q2 2022

Aug 09, 2022

BUY
$3.74 - $10.66 $121,924 - $347,516
32,600 Added 11.35%
319,900 $1.36 Million
Q1 2022

May 09, 2022

BUY
$7.81 - $20.45 $156,981 - $411,045
20,100 Added 7.52%
287,300 $2.73 Million
Q4 2021

Feb 08, 2022

BUY
$15.2 - $35.51 $22,800 - $53,265
1,500 Added 0.56%
267,200 $5.08 Million
Q3 2021

Nov 08, 2021

BUY
$21.78 - $40.45 $163,350 - $303,375
7,500 Added 2.9%
265,700 $8.84 Million
Q2 2021

Aug 06, 2021

BUY
$32.5 - $48.96 $581,750 - $876,384
17,900 Added 7.45%
258,200 $10 Million
Q1 2021

May 07, 2021

BUY
$41.61 - $54.3 $466,032 - $608,160
11,200 Added 4.89%
240,300 $11.6 Million
Q4 2020

Feb 05, 2021

BUY
$25.27 - $54.9 $128,877 - $279,990
5,100 Added 2.28%
229,100 $11.9 Million
Q3 2020

Nov 09, 2020

BUY
$18.49 - $27.24 $893,066 - $1.32 Million
48,300 Added 27.49%
224,000 $5.99 Million
Q2 2020

Aug 05, 2020

BUY
$8.9 - $21.84 $16,910 - $41,496
1,900 Added 1.09%
175,700 $3.42 Million
Q1 2020

May 08, 2020

BUY
$7.14 - $15.99 $74,970 - $167,895
10,500 Added 6.43%
173,800 $1.71 Million
Q4 2019

Feb 06, 2020

BUY
$5.1 - $11.2 $50,490 - $110,880
9,900 Added 6.45%
163,300 $1.81 Million
Q3 2019

Nov 12, 2019

BUY
$5.38 - $8.99 $69,402 - $115,971
12,900 Added 9.18%
153,400 $861,000
Q2 2019

Aug 02, 2019

BUY
$6.27 - $8.65 $146,091 - $201,545
23,300 Added 19.88%
140,500 $1.22 Million
Q4 2018

Feb 13, 2019

BUY
$3.44 - $5.76 $28,552 - $47,808
8,300 Added 7.62%
117,200 $481,000
Q3 2018

Nov 08, 2018

BUY
$5.15 - $14.0 $65,405 - $177,800
12,700 Added 13.2%
108,900 $610,000
Q1 2018

May 04, 2018

BUY
$8.7 - $16.8 $60,029 - $115,920
6,900 Added 7.73%
96,200 $1.37 Million
Q3 2017

Nov 03, 2017

BUY
$10.0 - $12.7 $893,000 - $1.13 Million
89,300
89,300 $1.06 Million

Others Institutions Holding TGTX

About TG THERAPEUTICS, INC.


  • Ticker TGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 145,274,000
  • Market Cap $4.61B
  • Description
  • TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...
More about TGTX
Track This Portfolio

Track Swiss National Bank Portfolio

Follow Swiss National Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

News

Stay updated on Swiss National Bank with notifications on news.